DRG Market Assessment reports

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…

Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-…

Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…

Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…

Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Geographic atrophy (GA) is an advanced stage of age-related macular degeneration characterized by the progressive and irreversible degeneration of retinal tissue, including photoreceptors. This…

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…